Adriana C Vidal1, Frank Duong2, Lauren E Howard3,4, Emily Wiggins4, Stephen J Freedland5,4, Neil A Bhowmick2, Jun Gong6. 1. Division of Urology, Department of Surgery, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, U.S.A. adriana.vidal@cshs.org. 2. Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, U.S.A. 3. Duke Cancer Institute, Duke University School of Medicine, Durham, NC, U.S.A. 4. Surgery Section, Durham VA Medical Center, Durham, NC, U.S.A. 5. Division of Urology, Department of Surgery, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, U.S.A. 6. Division of Hematology/Oncology, Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, U.S.A.
Abstract
BACKGROUND/AIM: We have previously found elevated levels of endoglin (CD105) in the prostate cancer (PC) tissue of men with poor prognosis, compared to men with indolent disease. Herein, we examined whether plasma levels of the soluble form of CD105 (sCD105) differ according to the PC grade at diagnosis. PATIENTS AND METHODS: We measured sCD105 in 73 subjects with biopsy-confirmed PC at the Durham, North Carolina, Veteran Affairs Health System. The association between sCD105 and intermediate/high-grade PC risk [Gleason Group (GG) 2-5 vs. 1] was examined using regression models. RESULTS: Of 73 men, 27 had low-grade PC and 46 high-grade PC. Higher GG was linked to lower sCD105 (GG1: 6938 pg/ml, GG2-3: 6150 pg/ml, GG4-5: 5554 pg/ml; p=0.012). On multivariable analysis, lower sCD105 was associated with increased high-grade PC risk (ORper 1000 units=1.33, p=0.028). CONCLUSION: Lower sCD105 levels were associated with intermediate and high-risk PC. Further investigation is warranted in a larger PC cohort. Copyright
BACKGROUND/AIM: We have previously found elevated levels of endoglin (CD105) in the prostate cancer (PC) tissue of men with poor prognosis, compared to men with indolent disease. Herein, we examined whether plasma levels of the soluble form of CD105 (sCD105) differ according to the PC grade at diagnosis. PATIENTS AND METHODS: We measured sCD105 in 73 subjects with biopsy-confirmed PC at the Durham, North Carolina, Veteran Affairs Health System. The association between sCD105 and intermediate/high-grade PC risk [Gleason Group (GG) 2-5 vs. 1] was examined using regression models. RESULTS: Of 73 men, 27 had low-grade PC and 46 high-grade PC. Higher GG was linked to lower sCD105 (GG1: 6938 pg/ml, GG2-3: 6150 pg/ml, GG4-5: 5554 pg/ml; p=0.012). On multivariable analysis, lower sCD105 was associated with increased high-grade PC risk (ORper 1000 units=1.33, p=0.028). CONCLUSION: Lower sCD105 levels were associated with intermediate and high-risk PC. Further investigation is warranted in a larger PC cohort. Copyright
Authors: Kazutoshi Fujita; Charles M Ewing; Lori J Sokoll; Debra J Elliott; Mark Cunningham; Angelo M De Marzo; William B Isaacs; Christian P Pavlovich Journal: Prostate Date: 2008-06-01 Impact factor: 4.104
Authors: Yasser M El-Gohary; Jan F Silverman; Peter R Olson; Yulin L Liu; Jeffrey K Cohen; Ralph Miller; Reda S Saad Journal: Am J Clin Pathol Date: 2007-04 Impact factor: 2.493
Authors: A V D'Amico; R Whittington; S B Malkowicz; D Schultz; K Blank; G A Broderick; J E Tomaszewski; A A Renshaw; I Kaplan; C J Beard; A Wein Journal: JAMA Date: 1998-09-16 Impact factor: 56.272
Authors: G Tsirakis; C A Pappa; M Spanoudakis; D Chochlakis; A Alegakis; F E Psarakis; M Stratinaki; E N Stathopoulos; M G Alexandrakis Journal: Eur J Intern Med Date: 2012-03-03 Impact factor: 4.487
Authors: Kazutoshi Fujita; Charles M Ewing; David Y S Chan; Leslie A Mangold; Alan W Partin; William B Isaacs; Christian P Pavlovich Journal: Int J Cancer Date: 2009-02-01 Impact factor: 7.396
Authors: Jonathan I Epstein; Michael J Zelefsky; Daniel D Sjoberg; Joel B Nelson; Lars Egevad; Cristina Magi-Galluzzi; Andrew J Vickers; Anil V Parwani; Victor E Reuter; Samson W Fine; James A Eastham; Peter Wiklund; Misop Han; Chandana A Reddy; Jay P Ciezki; Tommy Nyberg; Eric A Klein Journal: Eur Urol Date: 2015-07-10 Impact factor: 20.096
Authors: Anisha Madhav; Allen Andres; Frank Duong; Rajeev Mishra; Subhash Haldar; Zhenqiu Liu; Bryan Angara; Roberta Gottlieb; Zachary S Zumsteg; Neil A Bhowmick Journal: Oncogene Date: 2018-05-02 Impact factor: 9.867
Authors: Amanda B Hesterberg; Brenda L Rios; Elysa M Wolf; Colby Tubbs; Hong Yuen Wong; Kerry R Schaffer; Tamara L Lotan; Giovanna A Giannico; Jennifer B Gordetsky; Paula J Hurley Journal: J Pathol Clin Res Date: 2021-02-18
Authors: Hong Yuen Wong; Quanhu Sheng; Amanda B Hesterberg; Sarah Croessmann; Brenda L Rios; Khem Giri; Jorgen Jackson; Adam X Miranda; Evan Watkins; Kerry R Schaffer; Meredith Donahue; Elizabeth Winkler; David F Penson; Joseph A Smith; S Duke Herrell; Amy N Luckenbaugh; Daniel A Barocas; Young J Kim; Diana Graves; Giovanna A Giannico; Jeffrey C Rathmell; Ben H Park; Jennifer B Gordetsky; Paula J Hurley Journal: Nat Commun Date: 2022-10-13 Impact factor: 17.694